Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Director | April 03, 2026 | April 07, 2026 |
| SHOULDER INNOVATIONS, INC.SI · Entity 5607 | Director | October 05, 2026 | October 06, 2026 |
| Solana CoHSDT · Entity 6630 | Director | March 31, 2026 | April 02, 2026 |
| Xtant Medical Holdings, Inc.XTNT · Entity 7196 | Director | July 25, 2017 | July 27, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date April 03, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 178,733 |
Reported balance
After 2026-04-03 transaction · row 1
1 source rowRow 1 · 2026-04-03 · Grant · Acquired 41,929 · Balance 178,733 F1: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-04-02 | Direct | 26,036 |
Reported balance
After 2026-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-03 · Grant · Acquired 26,036 · Balance 26,036 F2: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
F2: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
SHOULDER INNOVATIONS, INC.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 65,025 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 1,275 · Balance 65,025 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Solana Co
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 92,004 |
Reported balance
After 2026-03-31 transaction · row 1
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 2,180 · Balance 92,004 F1: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. 75% of the RSUs vested on March 31, 2026, and the remaining 25% of RSUs will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2036-03-30 | Direct | 23,529 |
Reported balance
After 2026-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-31 · Grant · Acquired 23,529 · Balance 23,529 F2: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 75% of the options vested on March 31, 2026, and the remaining 25% of options will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. 75% of the RSUs vested on March 31, 2026, and the remaining 25% of RSUs will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period.
F2: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 75% of the options vested on March 31, 2026, and the remaining 25% of options will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period.
Xtant Medical Holdings, Inc.
Report date July 25, 2017 · Filed July 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,049 |
Reported balance
After 2017-07-25 transaction · row 1
1 source rowRow 1 · 2017-07-25 · Grant · Acquired 51,948 · Balance 72,049 F1: The common stock vests on July 25, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock vests on July 25, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Miromatrix Medical Inc.
Report date December 12, 2023 · Filed December 13, 2023
Section 16 reporting ended · disclosed 2023-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,201 |
Reported balance
After 2023-12-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-12-12 · Other · Disposed 52,593 · Balance 54,201 F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-12-13 · Disposition to issuer · Disposed 54,201 · Balance 0 F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2027-04-14 | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-13 · Disposition to issuer · Disposed 100,000 · Balance 0 F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2028-05-30 | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-13 · Disposition to issuer · Disposed 18,750 · Balance 0 F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2028-05-30 | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-12-13 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2029-07-25 | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-12-13 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.75 · Expires 2030-07-14 | Direct | 0 |
Reported balance
After 2023-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-12-13 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR").
F2: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company.
F3: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock.
F4: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award.
F5: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 6, 2026 20:42 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 1,275 | $19.60 | $24,990.00 |
DisclosureSEC source: 0001215243-26-000006 · wk-form4_1791319334.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,025 F1 · shares: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 21:00 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 5,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-26-000005 · wk-form4_1782766856.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,750 F1 · shares: Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2027 or June 26, 2027. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 17:28 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 26,036 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001215243-26-000004 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,036 Underlying: Common Stock · 26,036 shares Expires 2036-04-02 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 17:28 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 41,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-26-000004 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,733 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:00 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 23,529 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001215243-26-000003 · form4-04022026_050417.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,529 Underlying: Class A Common Stock · 23,529 shares Expires 2036-03-30 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 75% of the options vested on March 31, 2026, and the remaining 25% of options will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:00 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 2,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-26-000003 · form4-04022026_050417.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,004 F1 · shares: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. 75% of the RSUs vested on March 31, 2026, and the remaining 25% of RSUs will vest on June 30, 2026, subject to the Reporting Person's continued service through such vesting period. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Exercise / conversionStock Option · Derivative | 26,205 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · derivative · entry 6 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,205 shares Expires 2030-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and currently exercisable. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Exercise / conversionStock Option · Derivative | 19,401 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · derivative · entry 5 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,142 Underlying: Common Stock · 19,401 shares Expires 2033-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 36 equal monthly increments beginning on June 30, 2023. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Tax withholdingCommon Stock | 3,714 | $14.82 | $55,041.48 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · nonDerivative · entry 4 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,704 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Tax withholdingCommon Stock | 3,292 | $14.62 | $48,129.04 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · nonDerivative · entry 3 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,418 Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Exercise / conversionCommon Stock | 26,205 | $2.10 | $54,999.05 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · nonDerivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 21:38 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | Exercise / conversionCommon Stock | 19,401 | $2.48 | $48,122.24 |
DisclosureSEC source: 0001215243-26-000001 · wk-form4_1773783487.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following shares received without consideration as in-kind distributions: (i) 3,144 shares from cultivate(MD) Capital Accelerator Fund, L.P.; and (ii) 3,096 shares from Cultivate MD Capital Fund II, LP. In prior reports, the reporting person reported beneficial ownership of 13,864 shares of Shoulder Innovations common stock held directly. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionSeries D Convertible Preferred Stock · Derivative | 118,268 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022245 · ownership.xml · derivative · entry 3 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | GrantCommon Stock | 7,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-022245 · ownership.xml · nonDerivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,864 F2 · shares: Represents an award of restricted stock units ("RSUs"). The RSUs will vest on the earlier of the date of the annual meeting of stockholders to be held in 2026 or August 1, 2026. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:05 UTC | SHOULDER INNOVATIONS, INC. SI · Entity 5607 | ConversionCommon Stock | 6,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-022245 · ownership.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, the shares of preferred stock of the Issuer automatically converted into shares of Common Stock on a one-for-0.052410901 basis. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0001140361-25-024934 · form4.xml · derivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600 Underlying: Class A Common Stock · 2,600 shares Expires 2035-07-01 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of four (4) successive equal quarterly installments on the last day of each quarter starting on September 30, 2025, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 19:42 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001656026-25-000003 · primary_doc.xml · derivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 17:18 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 17,025 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001215243-25-000001 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,025 Underlying: Common Stock · 17,025 shares Expires 2035-02-14 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 17:18 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 27,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-25-000001 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,804 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:10 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 10,732 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001140361-25-000613 · form4.xml · derivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,732 Underlying: Class A Common Stock · 10,732 shares Expires 2035-01-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of four (4) successive equal quarterly installments on the last day of each quarter starting on March 31, 2025, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 21:02 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantWarrants (Right to Buy) · Derivative | 20,834 | $0.13 Strike: $1.19 | $2,604.25 |
DisclosureSEC source: 0001215243-24-000001 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 20,834 shares Expires 2027-08-01 F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 21:02 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 27,778 | $0.81 | $22,397.40 |
DisclosureSEC source: 0001215243-24-000001 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,026 Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 21:00 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001140361-24-032524 · form4.xml · derivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Class A Common Stock · 31,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. The options vest in a series of four (4) successive equal quarterly installments on the last day of each quarter starting September 30, 2024, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · derivative · entry 7 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-07-14 F5 · price: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. F5 · derivative.exercise_date: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · derivative · entry 6 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-07-25 F5 · price: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. F5 · derivative.exercise_date: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · derivative · entry 5 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-05-30 F5 · price: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. F5 · derivative.exercise_date: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 18,750 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · derivative · entry 4 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2028-05-30 F5 · price: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. F5 · derivative.exercise_date: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $3.75 | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · derivative · entry 3 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-04-14 F5 · price: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. F5 · derivative.exercise_date: In connection with the closing under the Merger Agreement, each employee stock option (right to buy) was canceled in exchange for (i) an amount in cash, without interest and less any required withholding tax, equal to the product of (A) the excess of the amount of the Cash Consideration over the exercise price per share of such stock option and (B) the number of shares that were subject to such stock option, without regard to vesting, and (ii) a number of CVRs equal to the same number of shares that were subject to such stock option, provided, that the payment, if any, under each CVR shall be reduced by the amount by which the exercise price per share exceeds the amount of the Cash Consideration. Read SEC document |
| December 13, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | Disposition to issuerCommon Stock | 54,201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · nonDerivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · security: Previously unvested restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's common stock. F4 · price: In connection with the closing under the Merger Agreement, each outstanding RSU award was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to the RSU award multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such RSU award. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 21:48 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | OtherCommon Stock | 52,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-016377 · form4-12132023_091236.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,201 F1 · shares: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F1 · price: Shares tendered and accepted pursuant to the terms of an offer conducted pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, United Therapeutics Corporation ("Parent") and Morpheus Subsidiary Inc., dated as of October 29, 2023, for consideration consisting of (i) $3.25 per share, payable in cash, without interest and less any required withholding taxes (the "Cash Consideration"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a "CVR"). F2 · price: Each CVR entitles the reporting person to potentially receive contingent payments of up to an aggregate of $1.75 per CVR, without interest and less any required withholding taxes, upon the achievement of a specified milestone in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "CVR Agreement"), dated as of December 12, 2023, by and between Parent and Continental Stock Transfer & Trust Company. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:24 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 54,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009216 · form4-06052023_080658.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paul R. Buckman Revocable Trust Disclosed balance after: 106,794 F1 · shares: The RSUs shall vest upon the earlier of (i) the next annual meeting of the stockholders of the Company or (ii) June 1, 2024. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:07 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 284,865 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001140361-23-026971 · form4.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 284,865 Underlying: Class A Common Stock · 284,865 shares Expires 2033-05-23 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. The options vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the options will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:07 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 83,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-026971 · form4.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,824 F1 · shares: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. The RSUs vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the RSUs will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 17:51 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 18,927 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001215243-23-000001 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,927 Underlying: Common Stock · 18,927 shares Expires 2033-03-16 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 17:51 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 20,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-23-000001 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,248 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| March 10, 2023 Filed Mar 30, 2023 20:59 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | PurchaseCommon Stock | 31,250 | $1.60 | $50,000.00 |
DisclosureSEC source: 0001415889-23-005634 · form4-03302023_080313.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Paul R. Buckman Revocable Trust Disclosed balance after: 52,593 Read SEC document |
| August 10, 2022 Filed Aug 16, 2022 13:43 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 12,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008659 · form4-08162022_060806.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul R. Buckman Revocable Trust Disclosed balance after: 21,343 F1 · shares: Restricted Stock Units ("RSUs") that will fully vest on the earlier of the next annual meeting or one year from the date of the grant. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 29,230 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001215243-22-000001 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,230 Underlying: Common Stock · 29,230 shares Expires 2032-05-31 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 29,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001215243-22-000001 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,672 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:40 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 21,605 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001140361-22-020582 · form4.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,605 Underlying: Class A Common Stock · 21,605 shares Expires 2032-05-22 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. The options vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the options will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:40 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 6,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020582 · form4.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,770 F1 · shares: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2022 Equity Incentive Plan. The RSUs vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the RSUs will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:10 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 2,547 | $0.00 Strike: $14.90 | $0.00 |
DisclosureSEC source: 0001209191-21-055888 · doc4.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,547 Underlying: Class A Common Stock · 2,547 shares Expires 2031-09-09 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2018 Omnibus Incentive Plan. The options vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the options will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:10 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 721 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-055888 · doc4.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 721 F1 · shares: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2018 Omnibus Incentive Plan. The RSUs vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the RSUs will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 22:01 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | ConversionSeries B-2 Preferred Stock · Derivative | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-007131 · edgar.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul R. Buckman Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B-2 Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · price: Each share of Series B-2 Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series B-2 Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 22:01 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | ConversionCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-21-007131 · edgar.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Paul R. Buckman Revocable Trust Disclosed balance after: 8,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B-2 Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 17:12 UTC | Miromatrix Medical Inc. MIRO · Entity 96164 | GrantCommon Stock | 5,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-007035 · edgar.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,555 F1 · shares: Restricted Stock Units ("RSUs") that will fully vest on the earlier of the next annual meeting or one year from the date of the grant. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:18 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 4,682 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001596771-21-000038 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,682 Underlying: Common Stock · 4,682 shares Expires 2031-06-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:18 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 4,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-21-000038 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,424 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. F2 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on March 31, 2021 whereby each three shares of common stock issued and outstanding prior to the split were combined and converted into one share of common stock. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:17 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 23,725 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001596771-20-000046 · primary_doc.xml · derivative · entry 2 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,725 Underlying: Common Stock · 23,725 shares Expires 2030-06-02 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:17 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-20-000046 · primary_doc.xml · nonDerivative · entry 1 BUCKMAN PAUL · CIK 0001215243 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,495 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.